Literature DB >> 12913404

Methodologic and clinical validation of the TIMI myocardial perfusion grade in acute myocardial infarction.

C Michael Gibson1, James A de Lemos, Sabina A Murphy, Susan J Marble, Kent W Dauterman, Andrew Michaels, Hal V Barron, Elliott M Antman.   

Abstract

Improved microvascular perfusion using the TIMI myocardial perfusion grade (TMPG) has been related to reduced in hospital, 30-day and 2-year mortality following thrombolytic administration. We sought to validate this measure using the more quantitative technique of digital subtraction angiography (DSA) and to correlate TMPG with ST segment resolution. DSA was used to analyze films from the LIMIT AMI acute myocardial infarction trial of front loaded r-tPA and rhuMAb CD18. Dye kinetics were also characterized using DSA in 88 arteries from patients without acute coronary syndromes in the absence of an obstructive lesion. Compared to normal patients, microvascular perfusion was reduced in acute myocardial infarction patients on DSA as demonstrated by a reduction in peak Gray (brightness) (p < 0.0001), the rate of rise in Gray/sec (p < 0.0001), the blush circumference (p < 0.0001), and the rate of growth in circumference (cm/sec) (p < 0.0001). However, while DSA perfusion was impaired overall in the setting of acute myocardial infarction, TMPG grade 3 in the setting of acute myocardial infarction did not differ from that in normal patients when studied quantitatively as shown by similar rates of growth in brightness and circumference (p = NS). ST resolution and the TMPG were significantly associated (p = 0.04). Compared to normal patients, acute myocardial infarction reduces the peak brightness of the myocardium, the rate of rise in brightness, the circumference of blush and the rate of growth in circumference as assessed using digital subtraction angiography. However, acute myocardial infarction patients with TMPG 3 had rates of growth in brightness and circumference that were nearly identical to normal patients. Thus, DSA validates that TMPG 3 is associated with normal kinetics of myocardial perfusion, and this likely accounts for the low (0.7%) 30 day mortality observed among those patients with TFG 3 and TMPG 3.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12913404     DOI: 10.1023/a:1025004911375

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  15 in total

1.  Rapid reduction of ST-segment elevation after successful direct angioplasty in acute myocardial infarction.

Authors:  G M Santoro; D Antoniucci; R Valenti; L Bolognese; P Buonamici; M Trapani; V Boddi; P F Fazzini
Journal:  Am J Cardiol       Date:  1997-09-15       Impact factor: 2.778

2.  Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction.

Authors:  Gregg W Stone; Michael A Peterson; Alexandra J Lansky; George Dangas; Roxana Mehran; Martin B Leon
Journal:  J Am Coll Cardiol       Date:  2002-02-20       Impact factor: 24.094

3.  Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators.

Authors:  E M Antman; R P Giugliano; C M Gibson; C H McCabe; P Coussement; N S Kleiman; A Vahanian; A A Adgey; I Menown; H J Rupprecht; R Van der Wieken; J Ducas; J Scherer; K Anderson; F Van de Werf; E Braunwald
Journal:  Circulation       Date:  1999-06-01       Impact factor: 29.690

4.  Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study.

Authors:  K W Baran; M Nguyen; G R McKendall; C T Lambrew; G Dykstra; S T Palmeri; R J Gibbons; S Borzak; B E Sobel; S G Gourlay; A C Rundle; C M Gibson; H V Barron
Journal:  Circulation       Date:  2001-12-04       Impact factor: 29.690

5.  Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators.

Authors:  E M Antman; C M Gibson; J A de Lemos; R P Giugliano; C H McCabe; P Coussement; I Menown; C A Nienaber; T C Rehders; M J Frey; R Van der Wieken; D Andresen; J Scherer; K Anderson; F Van de Werf; E Braunwald
Journal:  Eur Heart J       Date:  2000-12       Impact factor: 29.983

6.  ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14 investigators.

Authors:  J A de Lemos; E M Antman; R P Giugliano; C H McCabe; S A Murphy; F Van de Werf; C M Gibson; E Braunwald
Journal:  Am J Cardiol       Date:  2000-02-01       Impact factor: 2.778

7.  Impaired myocardial tissue perfusion early after successful thrombolysis. Impact on myocardial flow, metabolism, and function at late follow-up.

Authors:  A Maes; F Van de Werf; J Nuyts; G Bormans; W Desmet; L Mortelmans
Journal:  Circulation       Date:  1995-10-15       Impact factor: 29.690

8.  Prediction of short- and intermediate-term prognoses of patients with acute myocardial infarction using myocardial contrast echocardiography one day after recanalization.

Authors:  T Sakuma; Y Hayashi; K Sumii; M Imazu; M Yamakido
Journal:  J Am Coll Cardiol       Date:  1998-10       Impact factor: 24.094

9.  Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group.

Authors:  A W van 't Hof; A Liem; H Suryapranata; J C Hoorntje; M J de Boer; F Zijlstra
Journal:  Circulation       Date:  1998-06-16       Impact factor: 29.690

10.  Ability of the no-reflow phenomenon during an acute myocardial infarction to predict left ventricular dysfunction at one-month follow-up.

Authors:  M D Kenner; E J Zajac; G T Kondos; R Dave; J W Winkelmann; J Joftus; A Laucevicius; A Kybarskis; E Berukstis; A Urbonas
Journal:  Am J Cardiol       Date:  1995-11-01       Impact factor: 2.778

View more
  5 in total

1.  Current Assessments of the Adequacy of Myocardial Perfusion During Acute MI.

Authors:  Allen Chang; C Michael Gibson
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-05

2.  The never ending quest for an ideal angiographic surrogate of coronary reperfusion.

Authors:  Vijayakumar Subban; Ajit S Mullasari
Journal:  Indian Heart J       Date:  2012-12-26

3.  Coronary clearance frame count: a new index of microvascular perfusion.

Authors:  Armando Perez de Prado; Felipe Fernández-Vázquez; J Carlos Cuellas-Ramón; Ignacio Iglesias-Garriz
Journal:  J Thromb Thrombolysis       Date:  2005-04       Impact factor: 2.300

4.  Angiographic core laboratory reproducibility analyses: implications for planning clinical trials using coronary angiography and left ventriculography end-points.

Authors:  Terje K Steigen; Cheryl Claudio; David Abbott; Michael Schulzer; Jeff Burton; Wayne Tymchak; Christopher E Buller; G B John Mancini
Journal:  Int J Cardiovasc Imaging       Date:  2007-12-12       Impact factor: 2.357

5.  In vivo MRI and ex vivo histological assessment of the cardioprotection induced by ischemic preconditioning, postconditioning and remote conditioning in a closed-chest porcine model of reperfused acute myocardial infarction: importance of microvasculature.

Authors:  Tamás Baranyai; Zoltán Giricz; Zoltán V Varga; Gábor Koncsos; Dominika Lukovic; András Makkos; Márta Sárközy; Noémi Pávó; András Jakab; Csilla Czimbalmos; Hajnalka Vágó; Zoltán Ruzsa; Levente Tóth; Rita Garamvölgyi; Béla Merkely; Rainer Schulz; Mariann Gyöngyösi; Péter Ferdinandy
Journal:  J Transl Med       Date:  2017-04-01       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.